ArticleArchives of osteoporosis2026
Anti-osteoporosis medications in persons with and without Parkinson disease in Finland.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-osteoporosis medications in persons with and without Parkinson disease in Finland.Archives of osteoporosis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Contrary to reports on under-treatment in persons with Parkinson's disease, our study found similar anti-osteoporosis medication usage before and after their hip fractures among Finns with and without Parkinson's disease. Additional preventive measures may be needed to mitigate the high risk of hip fractures among persons with Parkinson's disease. PURPOSE: Parkinson's disease (PD) is associated with a doubled risk of hip fracture. However, previous reports suggest under-recognition of osteoporosis among persons with PD. Our study aimed to assess the annual prevalence of anti-osteoporosis medications among persons with and without PD in relation to diagnosis of PD and hip fractures.
methodsOur nationwide matched cohort design included 33,153 persons diagnosed with incident PD between 2000 and 2009 in Finland and 1:2 matched comparison cohort. Persons with previous hip fractures were excluded. Annual prevalences of anti-osteoporosis medications were calculated for each year between 5 years before and 10 years after diagnosis of PD, and between 5 years before and 5 years after the incident hip fractures.
resultsPrevalence of anti-osteoporosis medications was higher in persons with PD (3.62%, 95% confidence interval [CI] 3.28-3.98%) than those without PD (2.91%, 95% CI 2.70-3.14%), starting from 3 years before the diagnosis. Among individuals with incident hip fractures (1475 [13%] persons with PD and 1371 [6%] persons without PD), the annual prevalence were similar among persons with PD and without PD, peaking within 1 year after hip fractures (with PD: 20.3%, 95% CI 18.0-22.8%; without PD: 21.0%, 95% CI 18.5-23.6%).
conclusionContrary to reports on under-treatment in persons with PD, our study found similar anti-osteoporosis medication usage before and after their hip fractures among Finns with and without PD. Additional preventive measures, such as regular review of fall risk, is needed to mitigate the doubled risk of hip fracture in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.